Column Group funds trim Tenaya Therapeutics (TNYA) stake in Form 4

Rhea-AI Filing Summary

Tenaya Therapeutics major shareholder funds affiliated with The Column Group reported open-market sales of common stock.

On February 10, 2026, The Column Group III, LP and The Column Group III-A, LP reported selling 161,422 and 182,295 Tenaya Therapeutics shares, respectively, at a weighted average price of $0.8161, with individual trades between $0.80 and $0.84.

On February 11, 2026, affiliated funds reported additional sales of 1,905,115 and 2,151,458 shares at a weighted average price of $0.6808, with trades between $0.65 and $0.80. After these transactions, one affiliated fund reported indirectly holding 49,313,559 Tenaya shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COLUMN GROUP III GP, LP

(Last) (First) (Middle)

1 LETTERMAN DR

BLDG. D, STE. DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S		161,422	D	$0.8161(1)	4,253,298	I	See Footnote(2)
Common Stock	02/10/2026		S		182,295	D	$0.8161(1)	4,803,275	I	See Footnote(3)
Common Stock	02/11/2026		S		1,905,115	D	$0.6808(4)	2,348,183	I	See Footnote(2)
Common Stock	02/11/2026		S		2,151,458	D	$0.6808(4)	2,651,817	I	See Footnote(3)
Common Stock								49,313,559	I	See Footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

COLUMN GROUP III GP, LP

(Last) (First) (Middle)

1 LETTERMAN DR

BLDG. D, STE. DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

COLUMN GROUP III, LP

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BLDG. D, STE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

COLUMN GROUP III-A, LP

(Last) (First) (Middle)

1 LETTERMAN DR

BLDG. D, STE, DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group Opportunity III, LP

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BUILDING D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Column Group Opportunity III GP, LP

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BUILDING D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

TCG Opportunity III GP, LLC

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BUILDING D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kutzkey Tim

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BUILDING D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Svennilson Peter

(Last) (First) (Middle)

1 LETTERMAN DRIVE

BUILDING D, SUITE DM-900

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

2. The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

3. The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

5. The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Remarks:

Peter Svennilson and Tim Kutzkey have been added to this Form 4 as Reporting Persons as a result of the retirement of a managing partner of TCG III GP LP and a managing member of TCG Opportunity GP LLC.

	The Column Group III GP, LP /s/James Evangelista, Attorney-in-Fact	02/12/2026
	The Column Group III, LP by The Column Group III GP, LP, its general partner /s/ James Evangelista Attorney-in-Fact	02/12/2026
	The Column Group III-A, LP. by The Column Group III GP, LP, its general partner /s/ James Evangelista Attorney-in-Fact	02/12/2026
	/s/ James Evangelista, as Attorney-in-Fact for The Column Group Opportunity III LP	02/12/2026
	/s/ James Evangelista, as Attorney-in-Fact for The Column Group Opportunity III GP LP	02/12/2026
	/s/ James Evangelista, as Attorney-in-Fact for TCG Opportunity III GP, LLC	02/12/2026
	/s/ James Evangelista, as Attorney-in-Fact for Tim Kutzkey	02/12/2026
	/s/ James Evangelista, as Attorney-in-Fact for Peter Svennilson	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Column Group entities report for Tenaya Therapeutics (TNYA)?

Funds affiliated with The Column Group reported selling Tenaya Therapeutics common stock in open-market transactions. Sales occurred on February 10 and 11, 2026, at weighted average prices of $0.8161 and $0.6808 per share, according to the Form 4 filing.

How many Tenaya Therapeutics (TNYA) shares did Column Group funds sell?

Column Group-affiliated funds reported multiple Tenaya Therapeutics share sales, including blocks of 161,422, 182,295, 1,905,115 and 2,151,458 shares. These non-derivative transactions reflect significant open-market disposals of common stock by large shareholders classified as 10% owners.

At what prices were Tenaya Therapeutics (TNYA) shares sold by Column Group entities?

Reported sales used weighted average prices of $0.8161 and $0.6808 per share. Footnotes state individual trades on February 10 ranged from $0.80 to $0.84, while February 11 trades ranged from $0.65 to $0.80, all in Tenaya Therapeutics common stock.

Which Column Group entities are involved in the Tenaya Therapeutics (TNYA) Form 4?

Reporting persons include The Column Group III GP, LP, The Column Group III, LP, The Column Group III-A, LP, TCG Opportunity III LP and related general partner entities, as well as individuals Peter Svennilson and Tim Kutzkey associated as managing partners or members.

How many Tenaya Therapeutics (TNYA) shares remain held by a Column Group opportunity fund?

Following the reported transactions, one affiliated opportunity fund reported indirect beneficial ownership of 49,313,559 Tenaya Therapeutics common shares. This figure reflects a large remaining stake held through TCG Opportunity III LP, as described in the footnotes.

What do the Form 4 footnotes say about Column Group’s beneficial ownership of Tenaya (TNYA) shares?

Footnotes explain that specific limited partnerships directly hold the Tenaya shares, while general partners and managing partners may be deemed to share voting and investment power. They expressly disclaim beneficial ownership beyond their respective pecuniary interests in those securities.